A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
Status:
Completed
Trial end date:
2017-04-12
Target enrollment:
Participant gender:
Summary
This is a Phase 1b study investigating the safety and tolerability of IRl790 as adjunct
therapy in patients with Parkinson disease. IRL790/placebo is taken for 28 days.